Dyne Therapeutics (DYN)

• Market cap: $1.4B
• 1 day: -0.61%
• 5 days: 7.07%
• 1 month: 3.47%
• 3 months: -16.45%
• 6 months: -30.73%
• Year to date: -61.31%
• 1 year: -77.04%
• 5 years: -58.79%
• 10 years: -58.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Employees: 192

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

369% more call options, than puts

Call options by funds: $3.39M | Put options by funds: $724K

88% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 43

14% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 44

2% more funds holding

Funds holding: 199 [Q4 2024] → 203 (+4) [Q1 2025]

1.93% less ownership

Funds ownership: 109.64% [Q4 2024] → 107.72% (-1.93%) [Q1 2025]

29% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 5 (-2) [Q1 2025]

51% less capital invested

Capital invested by funds: $2.63B [Q4 2024] → $1.29B (-$1.34B) [Q1 2025]

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 9% downside
• Avg. target: $33 230% upside
• High target: $50 408% upside

11 analyst ratings

• positive: 10 91%
• neutral: 1 9%
• negative: 0 0%

Stifel Paul Matteis	265% upside $36	Buy Maintained	31 Jul 2025
RBC Capital Luca Issi	134% upside $23	Outperform Maintained	29 Jul 2025
Raymond James Martin Auster	215% upside $31	Outperform Reiterated	29 Jul 2025
Chardan Capital Keay Nakae	286% upside $38	Buy Maintained	29 Jul 2025
JP Morgan Tessa Romero	9% downside $9	Neutral Maintained	15 Jul 2025